Literature DB >> 8642696

Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.

Z Gu1, X Li, Y Quan, M A Parniak, M A Wainberg.   

Abstract

We have assessed interactions between the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) and a neutralizing monoclonal antibody (1E8) that hinders binding of deoxynucleoside triphosphate (dNTP) substrates. Steady-state reactions with homopolymeric template-primers revealed that 1E8 antagonized inhibition of RT activity mediated by 3'-azido-3'-deoxythymidine triphosphate and 2',3'-dideoxycytidine triphosphate. However, an additive or synergistic inhibition of RT polymerase activity was noted when 1E8 and the nonnucleoside RT inhibitors nevirapine and delavirdine were studied. Chain elongation and dNTP incorporation studies using an HIV-1 genome-derived heteropolymeric template and either oligodeoxynucleotide or tRNA3(Lys) as the primer yielded results consistent with the above observations. 1E8 also increased pausing at certain sites during synthesis of negative-strand, strong-stop DNA, whether or not ddNTP and nonnucleoside RT inhibitors were present.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642696      PMCID: PMC190112     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase.

Authors:  M H St Clair; C A Richards; T Spector; K J Weinhold; W H Miller; A J Langlois; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

2.  Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition.

Authors:  C Majumdar; J Abbotts; S Broder; S H Wilson
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

3.  Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching.

Authors:  H E Huber; J M McCoy; J S Seehra; C C Richardson
Journal:  J Biol Chem       Date:  1989-03-15       Impact factor: 5.157

4.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

5.  Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.

Authors:  E J Arts; J P Marois; Z Gu; S F Le Grice; M A Wainberg
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

6.  Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.

Authors:  Z Gu; Y Quan; Z Li; E J Arts; M A Wainberg
Journal:  J Biol Chem       Date:  1995-12-29       Impact factor: 5.157

7.  Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.

Authors:  Z Gu; E J Arts; M A Parniak; M A Wainberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

8.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

Authors:  R A Spence; W M Kati; K S Anderson; K A Johnson
Journal:  Science       Date:  1995-02-17       Impact factor: 47.728

9.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.

Authors:  H Mitsuya; R F Jarrett; M Matsukura; F Di Marzo Veronese; A L DeVico; M G Sarngadharan; D G Johns; M S Reitz; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.